IPP Bureau
Zydus granted Orphan Drug Designation by USFDA for ZYIL1
By IPP Bureau - March 22, 2023
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
CTSI appoints Harish Trivedi as CEO, South Asia
By IPP Bureau - March 22, 2023
PHARMAP 2023 to focus on pharmaceutical challenges and strategies
By IPP Bureau - March 22, 2023
The Congress gathers the whole value chain of the pharmaceutical industry on June, 12-13, 2023 in Switzerland
Glenmark receives ANDA approval for Prochlorperazine Maleate Tablets
By IPP Bureau - March 21, 2023
According to IQVIA sales data for the 12-month period ending January 2023, the Compazine Tablets, 5 mg and 10 mg market achieved annual sales of approximately US $26.9 million
Caplin receives USFDA approval for Rocuronium Bromide Injection
By IPP Bureau - March 21, 2023
Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)
Serum Institute of India likely front-runner to win supply of HPV vaccines for UIP, says GlobalData
By IPP Bureau - March 21, 2023
The Indian government will float a global tender in April 2023 to procure HPV vaccines.
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing
By IPP Bureau - March 21, 2023
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
AI platforms market for healthcare industry to reach $4.3 billion in 2024: GlobalData
By IPP Bureau - March 21, 2023
Various healthcare companies are already implementing high-tech solutions into existing healthcare systems.
Patritumab Deruxtecan shows better clinical activity in patient with lung and breast cancer
By IPP Bureau - March 20, 2023
Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session
Janssen announces novel dengue antiviral demonstrates efficacy in pre-clinical data
By IPP Bureau - March 20, 2023
The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans
Phase 3 data show Deuruxolitinib significantly improve scalp hair regrowth in Alopecia Areata
By IPP Bureau - March 20, 2023
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
Bliss GVS Pharma gets 3 minor observations from USFDA for Palghar unit
By IPP Bureau - March 19, 2023
The observations are procedural in nature
Nutricircle introduces nutrition based plant Protein isolates
By IPP Bureau - March 18, 2023
The objective of launching these products at AAHAR is to create awareness on the consumption of protein based products
Eiko LifeSciences to acquire 5% stake in Vivacious Pharmatex
By IPP Bureau - March 18, 2023
ELL will be the preferred source of supply for some the key Raw Materials to VPPL at "Arm's Length" transaction.
Lupin Digital Health reveals results of digital therapeutics study with ACS patients
By IPP Bureau - March 18, 2023
The one-year-long study was aimed to evaluate the efficacy of LDH's digital therapeutics platform
